Pariser AR - Search Results

1

Characteristics of rare disease marketing applications associated with FDA product approvals 2006-2010.

Pariser AR, Slack DJ, Bauer LJ, Warner CA, Tracy LA. Pariser AR, et al. Drug Discov Today. 2012 Aug;17(15-16):898-904. doi: 10.1016/j.drudis.2012.04.011. Epub 2012 May 5. Drug Discov Today. 2012. PMID: 22564486

2

Towards the international interoperability of clinical research networks for rare diseases: recommendations from the IRDiRC Task Force.

Nabbout R, Zanello G, Baker D, Black L, Brambilla I, Buske OJ, Conklin LS, Davies EH, Julkowska D, Kim Y, Klopstock T, Nakamura H, Nielsen KG, Pariser AR, Pastor JC, Scarpa M, Smith M, Taruscio D, Groft S. Nabbout R, et al. Among authors: pariser ar. Orphanet J Rare Dis. 2023 May 9;18(1):109. doi: 10.1186/s13023-023-02650-4. Orphanet J Rare Dis. 2023. PMID: 37161573 Free PMC article.

3

Therapies for inborn errors of metabolism: what has the orphan drug act delivered?

Talele SS, Xu K, Pariser AR, Braun MM, Farag-El-Massah S, Phillips MI, Thompson BH, Coté TR. Talele SS, et al. Among authors: pariser ar. Pediatrics. 2010 Jul;126(1):101-6. doi: 10.1542/peds.2009-3246. Epub 2010 Jun 21. Pediatrics. 2010. PMID: 20566615

4

Accelerating orphan drug development.

Coté TR, Xu K, Pariser AR. Coté TR, et al. Among authors: pariser ar. Nat Rev Drug Discov. 2010 Dec;9(12):901-2. doi: 10.1038/nrd3340. Nat Rev Drug Discov. 2010. PMID: 21119719

5

Regulatory considerations for developing drugs for rare diseases: orphan designations and early phase clinical trials.

Pariser AR, Xu K, Milto J, Coté TR. Pariser AR, et al. Discov Med. 2011 Apr;11(59):367-75. Discov Med. 2011. PMID: 21524390 Free article. Review.

6

Clinical pharmacology as a cornerstone of orphan drug development.

Bashaw ED, Huang SM, Coté TR, Pariser AR, Garnett CE, Burckart G, Zhang L, Men AY, Le CD, Charlab R, Gobburu JV, Lesko LJ. Bashaw ED, et al. Among authors: pariser ar. Nat Rev Drug Discov. 2011 Oct 31;10(11):795-6. doi: 10.1038/nrd3595. Nat Rev Drug Discov. 2011. PMID: 22037026

7

Rare cancer trial design: lessons from FDA approvals.

Gaddipati H, Liu K, Pariser A, Pazdur R. Gaddipati H, et al. Clin Cancer Res. 2012 Oct 1;18(19):5172-8. doi: 10.1158/1078-0432.CCR-12-1135. Epub 2012 Jun 20. Clin Cancer Res. 2012. PMID: 22718862

8

Important role of translational science in rare disease innovation, discovery, and drug development.

Pariser AR, Gahl WA. Pariser AR, et al. J Gen Intern Med. 2014 Aug;29 Suppl 3(Suppl 3):S804-7. doi: 10.1007/s11606-014-2881-2. J Gen Intern Med. 2014. PMID: 25029971 Free PMC article.

9

Investigational New Drug applications: a 1-year pilot study on rates and reasons for clinical hold.

Lapteva L, Pariser AR. Lapteva L, et al. Among authors: pariser ar. J Investig Med. 2016 Feb;64(2):376-82. doi: 10.1136/jim-2015-000010. J Investig Med. 2016. PMID: 26911627

10

Representation of Women and Minorities in Clinical Trials for New Molecular Entities and Original Therapeutic Biologics Approved by FDA CDER from 2013 to 2015.

Chen A, Wright H, Itana H, Elahi M, Igun A, Soon G, Pariser AR, Fadiran EO. Chen A, et al. Among authors: pariser ar. J Womens Health (Larchmt). 2018 Apr;27(4):418-429. doi: 10.1089/jwh.2016.6272. Epub 2017 Oct 19. J Womens Health (Larchmt). 2018. PMID: 29048983 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

36 results

Search Page

Filters